RESMED INC : Submission of Matters to a Vote of Security Holders (form 8-K)
November 22, 2019 at 04:17 pm EST
ottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:12pt;margin-bottom:0px"> FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
November 21, 2019
Date of Report (Date of earliest event reported)
ResMed Inc.
(Exact Name of Registrant as Specified in Charter)
Wall St set for higher open on megacaps boost; earnings, Fed comments on tap
Apr. 17
RE
Needham Adjusts ResMed's Price Target to $224 From $180, Maintains Buy Rating
Apr. 01
MT
ResMed Inc. Announces the U.S. Launch of the AirFit F40
Mar. 06
CI
Morgan Stanley Adjusts Resmed’s Price Target to AU$31.80 From AU$28.60, Keeps at Overweight
Mar. 05
MT
Evans & Partners Upgrades ResMed to Positive From Neutral, Price Target is AU$31
Mar. 04
MT
FTSE 100 Edges Higher on Leap Day, Boosted by Howden Joinery, Haleon Gains
Feb. 29
DJ
Australia shares slip as biotech firm CSL slumps on failed drug trial (Feb 12)
Feb. 11
RE
Powell, the paper tiger
Feb. 05
ANALYST RECOMMENDATIONS : Abbvie, Microsoft, Tesla, Alphabet, Booking...
Feb. 05
Mizuho Adjusts Price Target on ResMed to $215 From $195, Keeps Buy Rating
Jan. 30
MT
Oppenheimer Raises ResMed Price Target to $205 From $185, Maintains Outperform Rating
Jan. 30
MT
UBS Adjusts ResMed Price Target to $180 From $175, Maintains Neutral Rating
Jan. 25
MT
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
Jan. 25
MT
Oppenheimer Raises ResMed Price Target to $185 From $175, Maintains Outperform Rating
Jan. 25
MT
RBC Lifts Price Target on ResMed to $182 From $181, Cites 'Solid' Fiscal Q2 Results, Keeps Sector Perform Rating
Jan. 25
MT
ResMed Fiscal Q2 Non-GAAP Earnings, Revenue Increase; Shares Rise Premarket
Jan. 25
MT
ResMed Posts Lower Fiscal Q2 Profit; Shares Up 7%
Jan. 24
MT
ResMed Declares Q4 Dividend; Shares Jump 7%
Jan. 24
MT
ResMed beats estimates on strong sleep apnea device sales
Jan. 24
RE
ResMed Resumes Share Buyback Program With $50 Million of Repurchases in Fiscal Q2
Jan. 24
MT
ResMed Keeps Quarterly Cash Dividend at $0.48 a Share, Payable March 14 to Holders of Record Feb. 8
Jan. 24
MT
ResMed Fiscal Q2 Non-GAAP Earnings, Revenue Increases; Shares Jump After-Hours
Jan. 24
MT
ResMed Inc. Declares Quarterly Cash Dividend, Payable on March 14, 2024
Jan. 24
CI
Transcript : ResMed Inc., Q2 2024 Earnings Call, Jan 24, 2024
Jan. 24
Tranche Update on ResMed Inc.'s Equity Buyback Plan announced on February 27, 2014.
Jan. 24
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows:
- medical devices (50.4%);
- masks (37.9%);
- software as a service (11.7%).
At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia.
The United States accounts for 61.4% of net sales.
More about the company
Last Close Price
177.6
USD
Average target price
206.1
USD
Spread / Average Target
+16.01%
Consensus
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1